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OBJECTIVE—IGF-1 and the IGF-1 receptor (IGF-1R) have been
implicated in the regulation of adipocyte differentiation and lipid
accumulation in vitro.
RESEARCH DESIGN AND METHODS—To investigate the
role of IGF-1 receptor in vivo, we have inactivated the Igf-1r gene
in adipose tissue (IGF-1R
aP2Cre mice) using conditional gene
targeting strategies.
RESULTS—Conditional IGF-1R inactivation resulted in in-
creased adipose tissue mass with a predominantly increased lipid
accumulation in epigonadal fat pads. However, insulin-stimu-
lated glucose uptake into adipocytes was unaffected by the
deletion of the IGF-1R. Surprisingly, IGF-1R
aP2Cre mice exhibited
markedly increased somatic growth in the presence of elevated
IGF-1 serum concentrations, and IGF-1 mRNA expression was
signiﬁcantly increased in liver and adipose tissue. IGF-1 stimula-
tion of wild-type adipocytes signiﬁcantly decreased IGF-1 mRNA
expression, whereas the opposite effect was observed in IGF-1R–
deﬁcient adipocytes.
CONCLUSIONS—IGF-1R signaling in adipocytes does not ap-
pear to be crucial for the development and differentiation of
adipose tissue in vivo, but we identiﬁed a negative IGF-1R–
mediated feedback mechanism of IGF-1 on its own gene expres-
sion in adipocytes, indicating an unexpected role for adipose
tissue IGF-1 signaling in the regulation of IGF-1 serum concen-
trations in control of somatic growth. Diabetes 57:2074–2082,
2008
I
nsulin and the structurally related IGFs provide
essential signals for the control of embryonic and
postnatal development (1) through binding of their
respective tyrosine kinase receptors. Conventional
gene targeting strategies used to abrogate insulin receptor
and IGF-1 receptor (IGF-1R) signaling reveal severe phe-
notypes of both insulin receptor– and IGF-1R–deﬁcient
mice. While inactivating the insulin receptor results in
embryonic lethality (2), mice with a whole-body inactiva-
tion of the Igf-1r gene die shortly after birth (3), whereas
heterozygous Igf-1r knockout mice have increased longev-
ity, most likely due to greater resistance to oxidative stress
(4). These data point to a role of IGF-1R signaling in the
regulation of lifespan. To discern the relevance of IGF-1R
signaling in individual tissues, mice with tissue-speciﬁc
inactivation of the IGF-1R have been created. Tissue-
speciﬁc knockout of the Igf-1r gene in osteoblasts dis-
played signiﬁcant defects in bone formation with low
levels of osteoblastogenesis (5), revealing a function of the
IGF system in formation and maintenance of bone tissue.
Mice with simultaneous functional inactivation of both
insulin and IGF-1Rs in skeletal muscle have a low muscle
mass and display muscle hypoplasia (6), suggesting that
IGF-1 is a vital regulator of muscle development. Con-
versely, muscle-speciﬁc overexpression of IGF-1R resulted
in local myoﬁber hyperplasia (7). -Cell–speciﬁc deletion
of the IGF-1R did not alter islet development but led to
hyperinsulinemia and glucose intolerance in IGF-1RKO
mice (8). This model suggests that tissue-speciﬁc alter-
ations in the IGF-1 signaling might have secondary effects
on the organism.
Until now, the role of IGF-1R signaling in white adipose
tissue (WAT) has remained unclear. In 3T3-L1 adipocytes,
IGF-1 is an essential regulator of differentiation (9), and it
was recently shown that IGF-1 stimulates both cell growth
and lipogenesis during differentiation of human mesenchy-
mal stem cells into adipocytes in vitro (10). However, the
physiological role of IGF-1R signaling in adipose tissue in
vivo has not been systematically studied. To investigate
the role of the IGF-1R in the development and metabolism
of adipose tissue, we generated mice lacking the IGF-1R in
adipose tissue (IGF-1R
aP2Cre) using a conditional gene
targeting approach based on the Cre recombinase. Subse-
quently, we characterized the consequences of IGF-1R
deletion in adipose tissue on morphological and metabolic
parameters of IGF-1R
aP2Cre mice up to an age of 32 weeks.
RESEARCH DESIGN AND METHODS
Generation of IGF-1R
aP2Cre mice. IGF-1R
ﬂox/wt mice were created by
inserting loxP [locus of crossover (x) in bacteriophage P1] sites ﬂanking exon
3 of the Igf-1r gene using conditional gene targeting strategies and maintained
on a pure C57BL/6 genetic background. A targeting vector was constructed
encompassing 4.5 kb of intron 2 of the murine Igf-1r gene, a loxP site, an
FRT-ﬂanked neomycin resistance gene, 600-bp fragment containing exon 3, a
second loxP site, and 1.3 kb of intron 3. Cre-mediated recombination and
subsequent excision of exon 3 of the IGF-1R results in a frame shift after 213
codons, with an appended sequence of 27 amino acids followed by a stop
codon in exon 4. Gene targeting was performed in Bruce4 ES cells. For
transfection, 1  10
7 ES cells were transfected with 40 g DNA. G418/
Ganciclovir double-resistant colonies were picked 9 days after transfection
and expanded on 96-well tissue culture dishes. Genomic DNA was extracted
from each clone and analyzed by Southern blot and PCR analysis. Recovery,
microinjection, and transfer of 3.5 day postcoitum embryos were performed
according to standard procedures. Chimeric animals (80–90% chimerism
based on coat color) were bred with FlpE deleter on a C57BL/6 background.
Genotyping was performed by PCR on DNA extracted from tail biopsies using
From the
1Department of Medicine, University of Leipzig, Leipzig, Germany;
the
2Department of Mouse Genetics and Metabolism, Institute for Genetics,
University of Cologne and Center of Molecular Medicine Cologne, Cologne,
Germany; the
3Department of Internal Medicine II, University of Cologne
and Center of Molecular Medicine Cologne, Cologne, Germany; and the
4Interdisciplinary Center for Clinical Research (IZKF), Leipzig, Germany.
Corresponding authors: Jens C. Bru ¨ning, jens.bruening@uni-koeln.de; Mat-
thias Blu ¨her, bluma@medizin.uni-leipzig.de.
Received 29 October 2007 and accepted 22 April 2008.
Published ahead of print at http://diabetes.diabetesjournals.org on 28 April
2008. DOI: 10.2337/db07-1538.
N.K. and L.K. contributed equally to this work.
© 2008 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
ORIGINAL ARTICLE
2074 DIABETES, VOL. 57, AUGUST 2008customized primers: 5-TCC CTC AGG CTT CAT CCG CAA-3 (sense) and
5-CTT CAG CTT TGC AGG TGC ACG-3 (antisense). The targeting strategy is
shown in Fig. 1A. Mice on a mixed (C57BL/6  129/Sv) genetic background
carrying the aP2 Cre transgene were made by cloning a 1.4-kb SacI/SalI
complementary DNA fragment encoding the Cre recombinase, modiﬁed by
inclusion of a nuclear localization sequence and a consensus polyadenylation
signal, immediately downstream of the 5.4-kb promoter/enhancer of fatty
acid–binding protein aP2 (11).
IGF-1R
aP2Cre were derived by crossing IGF-1R
ﬂox/wt mice with IGF-1R
ﬂox/wt
mice expressing the Cre recombinase under the control of the aP2 promoter/
enhancer (IGF-1Rhet
aP2Cre). All mice were housed in pathogen-free facilities in
groups of three to ﬁve at 22  2°C on a 12-h light/dark cycle. Animals were fed
a standard chow diet (Altromin, Lage, Germany). In a subgroup of six to eight
female IGF-1R
AP2Cre and six wild-type mice, a high-fat diet study was
performed with a special high-fat diet containing 55.2% of calories from fat
(C1057; Altromin). Animals had ad libitum access to water at all times, and
food was only withdrawn if required for an experiment. All experiments were
performed in accordance with the rules for animal care of the local govern-
ment authorities (Bezirksregierung Ko ¨ln, Cologne, Germany) of the German
Government and were approved by the institutional animal care and use
committee.
Molecular characterization and genotyping of the IGF-1R
aP2Cre mice.
Genotyping was performed by PCR using genomic DNA isolated from the tail
tip. In brief, genomic DNA was prepared by using the DNeasy kit (Qiagen,
Hilden, Germany). The following two primer pairs were used to genotype
Igf-1r loxP sites, 5-TCC CTC AGG CTT CAT CCG CAA-3 (forward) and
5-CTT CAG CTT TGC AGG TGC ACG-3 (reverse), as well as the aP2 Cre
recombinase 5-CGC CGC ATA ACC AGT GAA AC-3 (forward) and 5-ATG
TCC AAT TTA CTG ACC G-3 (reverse). PCR was performed for 25 cycles
(loxP sites) or 30 cycles (aP2 Cre) of 95°C, 59°C (loxP sites), or 58°C (aP2
Cre), and 72°C (30 s each) using the Qiagen Taq Polymerase and a Peltier
Thermal Cycler PTC-200 (Bio-Rad, Hercules, CA). DNA from wild-type mice
produced a 300-bp band, and a 380-bp band was detected in IGF-1R lox mice
(Fig. 1B). For Western blot analysis, tissues were removed and homogenized
in homogenization buffer with an ultra-Turrax homogenizer (IKA Werke,
Stauffen, Germany), proteins were isolated using standard techniques, and
Western blot analysis was performed with antibodies raised against IGF-1R
-subunit (Santa Cruz Biotechnology, C20) and -actin (Abcam, Cambridge,
U.K.) as loading control.
Phenotypic characterization. Ten mice of each genotype (IGF-1R
aP2Cre,
IGF-1Rhet
aP2Cre, wild-type, IGF-1R
ﬂox/ﬂox, and aP2 Cre) of both sexes were
studied from an age of 4 weeks up to 32 weeks of life. Body weight was
recorded weekly up to an age of 14 weeks, and thereafter in 2-week intervals;
body length (naso-anal length) was measured once at week 32. At an age of 16
weeks, both sexes of a subgroup of 20 (10 IGF-1R
aP2Cre and 10 controls)
underwent a food intake measurement over a time period of 1 week. The daily
food intake was calculated as the average intake of chow within the time
stated. Intraperitoneal glucose tolerance tests (GTTs) and insulin tolerance
tests (ITTs) were performed at the age of 12 and 24 weeks. GTT was
performed after an overnight fast for 16 h by injecting 2 g/kg body wt glucose
and measuring the blood glucose levels after tail vein incision at 0 (baseline),
10, 30, 60, and 120 min after injection. ITT was performed in random-fed
animals by injecting 0.75 unit/kg body wt human regular insulin (40 units
Actrapid; Novo Nordisk, Copenhagen, Denmark). Glucose levels were deter-
mined in blood collected from the tail tip immediately before and 15, 30, and
60 min after the intraperitoneal injection.
Mice were killed at the age of 32 weeks by an overdose of anesthetic
(Sevoﬂuran, Abbott, Germany). Liver, heart, brain, lung, spleen, subcutane-
ous, and epigonadal adipose tissue were immediately removed. The organs
were weighed and related to the whole-body mass to obtain relative organ
weights. Serum was collected at 32 weeks, and concentrations of insulin,
leptin, adiponectin, and IGF-1 were measured.
Analytical procedures. Blood glucose values were determined from whole–
venous blood samples using an automated glucose monitor (GlucoMen;
Menarini Diagnostics, Wokingham, U.K.). Insulin, leptin, growth hormone
(GH), and adiponectin serum concentrations were measured by ELISA using
mouse standards according to the manufacturer’s guidelines (Mouse/Rat
Insulin ELISA; Linco, St. Charles, MO) (Mouse Leptin ELISA and Mouse
Adiponectin/Acrp30 ELISA; R&D Systems, Minneapolis, MN). IGF-1 serum
concentrations were measured by a radioimmunoassay (Mediagnost, Reutlin-
gen, Germany).
Adipocyte isolation, size distribution, and primary culture. Animals
were killed, and subcutaneous and epididymal fat pads were removed.
Adipocytes were isolated by 1 mg/ml collagenase digestion. To determine cell
size distribution and adipocyte number, 200-l aliquots of adipocytes were
ﬁxed with osmic acid, incubated for 48 h at 37°C, and counted in a Coulter
counter (Multisizer III; Beckman Coulter, Krefeld, Germany). Isolated adipo-
cytes were resuspended in Dulbecco’s modiﬁed Eagle’s medium/F-12 Ham’s
medium (Sigma, St. Louis, MO) and centrifuged at 350  g for 10 min to
separate mature adipocytes from the stromal vascular cell pellet, which was
discarded. Floating fat-ﬁlled adipocytes were than incubated for 6 h with
different concentrations (0, 0.1, 1, 10, and 100 ng/ml recombinant IGF-1 (U.S.
Biological, Swampscott, MA).
Histology. Tissue was ﬁxed in 4% buffered formaldehyde, trimmed into small
cubes, rinsed in phosphate-buffered saline, and dehydrated in a graded series
of 50–100% ethanol followed by propylene oxide. Tissue was inﬁltrated with
propylene:epon 812 mixtures by increasing the resin concentration gradually.
Sections at 0.5 m were cut with a Reichert ultramicrotome, mounted on
polylysine-covered object slides and stained with azur-II-methylene blue
(Richardson stain). Digitized pictures were taken with the light microscope
Axioplan 2 (Zeiss, Jena, Germany) using the measurement facilities of Imagic
Access (Imagic, Glattburg, Switzerland). Multiple sections (separated by
70–80m each) were obtained from gonadal and subcutaneous fat pads and
analyzed systematically with respect to adipocyte size and number. For each
genotype and sex, at least 10 ﬁelds (representing 100 adipocytes) per slide
were analyzed.
Glucose transport. For the determination of glucose transport, isolated
adipocytes from the different fat depots were stimulated with 100 nmol/l
insulin for 30 min and then incubated for 30 min with 3 mol/l [U-
14C]glucose.
Immediately after incubation, adipocytes were ﬁxed with osmic acid and
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FIG. 1. Targeting strategy, assessment of IGF-1R recombination, and
IGF-1R expression. A: Schematic representation of the loxP-ﬂanked
IGF-1R allele before and after recombination (Cre-expression). The
knockout allele is shown below the ﬂoxed allele, indicating the dele-
tion of exon 3 in the event of recombination of the igf-1r gene. BamHI,
restriction sites; triangle, loxP site; ellipse, FRT site. B: Results from
PCR analysis of DNA prepared from isolated adipocytes. DNA from
isolated adipocytes of wild-type mice produced a 300-bp band (lane 1),
whereas a single 380-bp band was detected for IGF-1R
aP2Cre mice (lane
3). Heterozygous expression of the transgene was detected by both a
300-bp and a 380-bp band (lane 2). C: Western blot analysis for IGF-1R
-subunit and -actin as loading control of WAT, liver, brain, and
skeletal muscle of two representative wild-type (WT) and IGF-1R
aP2Cre
mice.
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been decolorized (12).
Tissue-speciﬁc IGF-1 mRNA expression. IGF-1 mRNA expression was
measured by quantitative real-time PCR using the standard curve method in a
ﬂuorescent temperature cycler using the TaqMan assay. Fluorescence was
detected on an ABI PRISM 7000 sequence detector (Applied Biosystems,
Darmstadt, Germany). Total RNA was extracted from epigonadal and subcu-
taneous WAT, primary adipocyte culture after incubation with or without
IGF-1, liver, brain, skeletal muscle, and brown adipose tissue (BAT) using
TRIzol (Life Technologies, Grand Island, NY), and 1 g RNA was reverse
transcribed with standard reagents (Life Technologies, Grand Island, NY).
From each RT-PCR, 2 l was ampliﬁed in a 26-l PCR using the Brilliant SYBR
Green QPCR Core Reagent kit from Stratagene (La Jolla, CA) according to
manufacturer’s instructions. The following primer pairs were used: muIGF-1,
5-GCTGCTGAAGCCATTCATTT-3 (sense) and 5-TTGCTCTTAAGGAGGC-
CAAA-3 (antisense); mu36B4, 5-aacatgctcaacatctcccc-3 (sense) and 5-
ccgactcctccgactcttc-3 (antisense). Expression of IGF-1 and 36B4 mRNA were
quantiﬁed by using the second derivative maximum method of the TaqMan
software (Applied Biosystems) determining the crossing points of individual
samples by an algorithm that identiﬁes the ﬁrst turning point of the ﬂuores-
cence curve. Ampliﬁcation of speciﬁc transcripts was conﬁrmed by melting
curve proﬁles (cooling the sample to 68°C and heating slowly to 95°C with
measurement of ﬂuorescence) at the end of each PCR.
Data analysis and statistics. Data are given as means  SD. Datasets were
analyzed for statistical signiﬁcance using a two-tailed unpaired Student’s t
test, or differences were assessed by one-way ANOVA corrected by Bonfer-
roni-Holm using the Statistical Package for Social Science, version 14.0 (SPSS,
Chicago, IL). P values 0.05 were considered signiﬁcant.
RESULTS
Generation of IGF-1R
aP2Cre mice. Mice lacking the
IGF-1R in adipose tissue (IGF-1R
aP2Cre) were generated by
crossing mice carrying the loxP-ﬂanked Igf-1r allele with
transgenic mice expressing the Cre recombinase under
control of the adipose-speciﬁc fatty acid binding protein
(aP2) promoter. The targeting strategy is shown in Fig. 1A.
IGF-1R
aP2Cre mice were obtained with the expected Men-
delian frequency. Cre expression was expected to be
restricted to WAT and BAT. PCR analysis of the genomic
DNA showed that the wild-type Igf-1r allele was absent in
IGF-1R
aP2Cre, whereas IGF-1Rhet
aP2Cre mice contained
both the wild-type and loxP-ﬂanked Igf-1r allele (Fig. 1B).
Western blot analysis of adipose tissue lysates clearly
indicated that Igf-1r protein was reduced by 90% in WAT
of IGF-1R
aP2Cre mice (Fig. 1C) and completely lost in BAT
(data not shown). A 40% reduction of IGF-1R protein
expression was found in the brain, whereas no changes in
the overall expression of the IGF-1R protein were detected
in liver, skeletal muscle (Fig. 1C), kidney, and bone (data
not shown). IGF-1R expression was unaffected in all
tissues of wild-type, IGF-1R
ﬂox/ﬂox, and aP2 Cre mice,
indicating that neither the loxP modiﬁcation of the IGF-1R
locus nor expression of the aP2 transgene alone affects
IGF-1R expression. These genotypes (wild type, IGF-
1Rlox/lox, and aP2 Cre) had similar physiological and
metabolic characteristics and were therefore considered
controls in all subsequent analyses.
Phenotype of IGF-1R
aP2Cre mice. Both sexes of IGF-
1R
aP2Cre mice exhibited normal growth until the age of 10
weeks. However, by 10 weeks of age male and female
IGF-1R
aP2Cre mice had gained more weight than control
group littermates (Fig. 2A and B). Moreover, we found that
IGF-1R
aP2Cre mice had signiﬁcantly increased naso-anal
body length when compared with littermate controls (fe-
males, P  0.01; and males, P  0.001) at an age of 24 and
32 weeks (Fig. 2C). Heterozygous deﬁciency of the Igf-1r
gene had no signiﬁcant inﬂuence on body growth and
weight (data not shown). Daily food intake was indistin-
guishable between IGF-1R
aP2Cre mice and all control
groups (data not shown). Because IGF-1R
aP2Cre mice ex-
hibit 15% increased body weight, organ and fat pad
weights were calculated as percentage of the whole-body
weight at an age of 24 weeks. We found a disproportional
increase of fat pad (Fig. 2D), liver (Fig. 2E), and heart
weights in IGF-1R
aP2Cre mice. In contrast, relative brain
weight was signiﬁcantly reduced in IGF-1R
aP2Cre com-
pared with controls (Fig. 2F). Relative organ weights of
BAT (Fig. 2G), skeletal muscle, kidney, spleen, and bone
were not different between IGF-1R
aP2Cre mice and control
mice (data not shown).
Metabolic parameters. To determine the physiological
consequences of reduced adipose tissue IGF-1R expres-
sion, we monitored blood glucose, insulin, total choles-
terol, and triglyceride concentrations and performed serial
glucose and ITTs over an age range from 12 to 32 weeks
(Table 1). Fasted blood glucose was signiﬁcantly higher in
IGF-1R
aP2Cre mice at an age of 12 weeks, whereas no such
differences were found at 24 weeks of age (Table 1). In
parallel, fed blood glucose was signiﬁcantly higher at an
age of 12 weeks in males (Table 1). There were no differences
in serum insulin and leptin concentrations between IGF-
1R
aP2Cre and control mice at 12 and 24 weeks (Table 1).
Cholesterol and triglyceride serum concentrations were
also not signiﬁcantly different between IGF-1R
aP2Cre and
control mice (Table 1). Adiponectin serum concentrations
were higher in control compared with IGF-1R
aP2Cre mice,
however, these differences were only signiﬁcant at 12
weeks (Table 1). Independent of age, intraperitoneal GTTs
demonstrated normal glucose tolerance in male (Fig. 3A
and B) and female (data not shown) IGF-1R
aP2Cre and
control mice. Intraperitoneal ITTs at 12 and 24 weeks of
age in male (Fig. 3C and D) and female mice (data not
shown) were indistinguishable between IGF-1R
aP2Cre and
control mice. Taken together, reducing IGF-1R expression
in adipose tissue results in increased somatic growth in
the absence of major metabolic alterations.
IGF-1 serum concentration is markedly increased in
IGF-1R
aP2Cre mice. Because IGF-1R
aP2Cre mice exhibited
an increased postnatal somatic growth, we next deter-
mined circulating plasma IGF-1 concentrations as the
major determinant of somatic growth in mammals. IGF-1
serum concentration is signiﬁcantly increased in IGF-
1R
aP2Cre mice starting at an age of 12 weeks up to 24 weeks
of age (Fig. 4A). In parallel to higher IGF-1 serum concen-
trations, we found signiﬁcantly higher serum concentra-
tions of the IGF binding protein (IGFBP)-3 (Fig. 4B). On
the other hand, serum concentrations of IGFBP-1 and -2
were not signiﬁcantly different between IGF-1R
aP2Cre and
control mice (data not shown). GH and IGF-2 serum
concentrations were indistinguishable between IGF-
1R
aP2Cre and control mice (Table 1), indicating that dys-
regulation of IGF-1 concentrations is not a result of altered
pituitary regulation and thus appears to be primarily
regulated in peripheral organs of IGF-1R
aP2Cre mice. There-
fore, we determined IGF-1 and IGFBP-3 mRNA expression
in adipose tissue and liver of IGF-1R
aP2Cre and control
mice to assess whether increased IGF-1 and IGFBP-3
serum concentrations correlate with increased expression
in those organs important for the synthesis of these
molecules. We found signiﬁcantly higher IGF-1 mRNA
expression both in adipose tissue (Fig. 4C) and liver (Fig.
4D) of IGF-1R
aP2Cre mice. In parallel, there was a trend for
increased IGFBP-3 mRNA expression in liver and adipose
tissue of IGF-1R
aP2Cre compared with control mice (data
not shown).
To determine whether increased adipose tissue IGF-1
ROLE OF IGF-1 IN ADIPOCYTES
2076 DIABETES, VOL. 57, AUGUST 2008expression in IGF-1R
aP2Cre mice was the result of an
altered adipocyte autonomous autocrine regulatory loop,
we isolated adipocytes from wild-type and IGF-1R
aP2Cre
mice. Treatment of control adipocytes with recombinant
IGF-1 (100 ng/ml) for 6 h ex vivo caused a signiﬁcant
reduction of its own mRNA expression (Fig. 4E). Con-
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FIG. 2. Growth phenotype of IGF-1R
aP2Cre mice and controls. IGF-1R
aP2Cre mice show identical growth until an age of 10 weeks. Thereafter, body
weight of IGF-1R
aP2Cre mice is signiﬁcantly increased both in males (A) and females (B) until an age of 32 weeks. *P < 0.05, **P < 0.01, ***P <
0.001. C: Body length (naso-anal length) is markedly increased in IGF-1R
aP2Cre mice at an age of 24 weeks (n  10 per genotype and sex). D–F:
Organ weights relative to body weight in 24-week-old IGF-1R
aP2Cre and control mice (n  10 per genotype and sex). IGF-1R
aP2Cre mice exhibit
increased relative epigonadal fat pad (D) and liver weight (E). Relative brain weight (F) was signiﬁcantly reduced in IGF-1R
aP2Cre mice, possibly
as a consequence of heterozygous transgene (aP2) expression in brain, whereas relative BAT weight (G) was indistinguishable between
IGF-1R
aP2Cre and control mice.
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aP2Cre mice, stimulation
with IGF-1 did not inhibit IGF-1 mRNA expression but
rather resulted in a paradoxical stimulation of IGF-1
mRNA expression.
Consequences of IGF-1R knockout on adipose tissue
morphology and metabolism. Adipose tissue mass is
increased in IGF-1R
aP2Cre mice compared with controls
(Fig. 2D). The increased adipose tissue mass was related
to both increased number and mean volume of adipocytes
in IGF-1R
aP2Cre mice (data not shown). Mean adipocyte
size (diameter) is signiﬁcantly higher in IGF-1R
aP2Cre
(105.4  12 m) when compared with control (87.3  9.3
m) mice (P  0.05). These differences are more pro-
nounced in epigonadal than in subcutaneous fat (Fig. 5A
and B). We found a 1.4-fold increase in insulin receptor
mRNA expression in adipocytes from IGF-1R
aP2Cre mice
TABLE 1
Metabolic parameters in 12- and 24-week-old male and female IGF-1R
aP2Cre and control mice
Age (weeks)
Males Females
Control IGF-1R
aP2Cre Control IGF-1R
aP2Cre
n 10 10 10 10
Blood glucose, fasted (mg/dl) 12 82  18* 111  35 74  17† 99  20
24 91  22 106  33 88  18 91  20
Blood glucose, fed (mg/dl) 12 149  16† 169  15 141  18 147  16
24 144  17 153  12 137  15 140  15
Serum insulin, fasted (ng/ml) 24 1.8  1.5 1.5  0.5 0.4  0.2 0.6  0.4
Serum leptin, fed (pg/ml) 24 10.1  4.8 8.2  4.8 10.6  5.4 12.1  5.2
Growth hormone, fed (ng/ml) 24 11.4  5.2 10.8  6.1 9.5  4.7 10.2  5.8
IGF-2, fed (g/ml) 24 1.13  0.5 1.08  0.4 0.97  0.6 1.11  0.6
Serum adiponectin, fed (ng/ml) 12 7.5  1.6‡ 4.7  0.8 16.1  1.2‡ 8.9  2.2
24 9.5  4.1 6.4  1.9 16.5  6.8 12.5  7.7
Serum cholesterol, fed (mmol/l) 24 2.5  0.5 2.4  0.5 1.9  0.3 2.1  0.2
Serum triglycerides, fed (mmol/l) 24 1.7  0.7 1.5  0.9 1.1  0.1 1.8  1.2
Signiﬁcant differences from control: *P  0.05, †P  0.01, ‡P  0.001.
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FIG. 3. IGF-1R
aP2Cre mice have normal glucose tolerance and insulin sensitivity. A and B: GTTs performed on 12-h-fasted 12-week old (A) and
24-week-old (B) male wild-type (control) and IGF-1R
aP2Cre mice. Results are expressed as means  SE from 10 animals per genotype. C and D:
ITTs on random fed 12-week-old (C) and 24-week-old (D) male wild-type (control) and IGF-1R
aP2Cre mice. Results are expressed as means  SE
from 10 animals per genotype.
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knockout on adipocyte glucose transport, basal and insu-
lin-stimulated glucose uptake in isolated adipocytes was
studied. In adipocytes from IGF-1R
aP2Cre mice, basal glu-
cose uptake is unchanged compared with wild-type mice
(Fig. 5C). Insulin stimulated glucose uptake is 2.8-fold in
IGF-1R
aP2Cre and 2.1-fold in wild-type adipocytes (P 
0.05). Despite larger adipocyte size in IGF-1R
aP2Cre mice,
we found signiﬁcantly increased insulin sensitivity in
IGF-1R
aP2Cre compared with wild-type adipocytes.
DISCUSSION
IGFs (IGF-1 and -2) lead to many different biological effects
in target cells such as hepatocytes, myocytes, and adipocytes
(13). IGF-1 action is propagated by the IGF-1R. IGF-1R–
deﬁcient mice are severely growth retarded, exhibit multiple
growth- and differentiation-dependent abnormalities, and die
shortly after birth (3). Disruption of IGF-1R in speciﬁc tissues
or cell types such osteoblasts (5), skeletal muscle (6), and
-cells (8) further revealed an essential role of IGF-1R
signaling in differentiation and growth.
IGF-1 was shown to be an essential regulator of differ-
entiation in 3T3L1 adipocytes (9). Moreover, IGF-1 stimu-
lates both cell growth and lipogenesis during differentiation
of human mesenchymal stem cells into adipocytes in vitro
(10). However, the physiological role of the IGF-1R signal-
ing in adipose tissue in vivo has not been systematically
studied. We therefore created mice lacking the IGF-1R in
adipose tissue (IGF-1R
aP2Cre mice). To speciﬁcally target
adipose tissue, we used transgenic mice that express the
Cre recombinase cDNA from the adipose-speciﬁc fatty
acid binding protein (aP2) promoter/enhancer (14). aP2
Cre mice have been used for adipose-selective inactivation
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Unexpectedly, deletion of IGF-1R was not restricted to
WAT and BAT. In most IGF-1R
aP2Cre mice, we found a
reduction of IGF-1R protein also in the brain, suggesting
transgene expression in neuronal tissue in addition to fat.
Although aP2 promoter provides adipocyte-restricted ex-
pression postnatally, it was recently shown that aP2 has a
wider embryonic expression pattern than previously ap-
preciated (17). Throughout embryonic development, the
aP2 Cre transgene was consistently found in different cell
types of the nervous system (17). Expression of the aP2
Cre transgene during embryonic development might ex-
plain the reduced relative brain mass in IGF-1R
aP2Cre mice.
We excluded aP2 Cre transgene expression in other tis-
sues, including liver and skeletal muscle, by protein ex-
pression analyses. Whole-body expression of the
transgene would cause growth retardation as demon-
strated in IGF-1r
/	 mice (4,18). In contrast, IGF-1R
aP2Cre
mice have increased somatic growth, further suggesting
that tissues other than fat and brain are not affected by the
ectopic aP2-Cre transgene expression. However, we have
to discuss our data with the caution that reduced IGF-1R
expression in the brain may contribute to the phenotype of
IGF-1R
aP2Cre mice. IGF-1R
aP2Cre mice are viable and fertile
and do not exhibit growth retardation.
We demonstrate that IGF-1R
aP2Cre mice have increased
somatic growth starting at an age of 10 weeks. IGF-
1R
aP2Cre mice are both longer and heavier than their
wild-type littermates. The increased growth is not the
result of increased food intake in IGF-1R
aP2Cre mice.
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FIG. 5. Hypertrophy of adipocytes in WAT and normal insulin stimu-
lated glucose uptake into isolated adipocytes of IGF-1R
aP2Cre mice. A:
Hematoxylin-eosin staining of WAT (epigonadal and subcutaneous)
and BAT sections from random-fed, 24-week-old male IGF-1R
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1R
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adipocyte size is signiﬁcantly increased in IGF-1R
aP2Cre mice. C: Rela-
tive glucose uptake into isolated adipocytes from 24-week-old male
IGF-1R
aP2Cre and wild-type (control) mice. Insulin stimulation was
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relative organ weights than other organs, including kidney,
skeletal muscle, and spleen, which are increased in size
proportionally to the higher body weight of IGF-1R
aP2Cre
mice. Increased growth in IGF-1R
aP2Cre mice is most likely
the result of an 20% increased IGF-1 serum concentra-
tions. In patients with acromegaly, elevated circulating
IGF-1 levels cause increased adult growth and, at least in
some patients, may lead to enlarged organs, including
hepatomegaly (19) and acromegalic cardiomyopathy (20).
In analogy to the phenotype of IGF-1R
aP2Cre mice, trans-
genic expression of human IGF-1 in mice causes a similar
phenotype with 1.3-fold increased weight as a result of
selective organomegaly without an apparent increase in
skeletal growth (21). Moreover, liver-speciﬁc IGF-1 over-
expression causes 50% increased serum IGF-I levels and
enhanced somatic growth (22).
Because circulating GH and IGF-2 levels are normal,
increased IGF-1 serum levels in IGF-1R
aP2Cre mice are
most likely the result of increased IGF-1 expression both
in adipose tissue and liver and not of changes caused by an
IGF-1R deﬁciency in the central nervous system. It is
difﬁcult to dissect whether adipose or liver-derived IGF-1
primarily increases circulating IGF-1 levels. Interestingly,
we identiﬁed a negative feedback mechanism for IGF-1
mRNA expression in adipose tissue. In wild-type adipo-
cytes, IGF-1 suppressed its own mRNA expression ex vivo,
whereas this negative feedback was blunted in adipocytes
isolated from IGF-1R
aP2Cre mice. However, increased
IGF-1 expression in liver is more difﬁcult to explain.
It is difﬁcult to dissect whether adipose or liver-derived
IGF-1 primarily increases circulating IGF-1 levels. Our
experimental design does not allow for the distinction
between hepatic or adipose tissue–derived IGF-1. It has
been shown that IGF-1 and IGF-1R mRNA levels are
differentially regulated in different tissues (23). Interest-
ingly, presumably adipose tissue–derived IGF-1 does not
inhibit hepatic IGF-1 expression as it was shown in the
liver of GH-deﬁcient dwarf rats after IGF-1 treatment (24).
Another potential explanation for the absence of a nega-
tive feedback of IGF-1 on its own expression in liver might
be that hepatocytes only express the IGF-1R in very little
amounts (25). Alternatively, circulating IGF-1 could be
modulated indirectly by affecting its binding proteins.
Increased IGFBP-3 mRNA expression in liver in response
to increased circulating IGF-1 from adipose tissue could
be a potential mediator. Increase in IGFBP-3 was the best
and independent predictor of increased IGF-1 serum con-
centrations in our IGF-1R
aP2Cre mice (27).
Moreover, deletion of the IGF-1 gene in liver demon-
strated that liver-derived IGF-1 is not crucial for somatic
growth (26), suggesting that increased somatic growth in
IGF-1R
aP2Cre mice is primarily due to increased adipose
tissue expression. However, previous data suggest that
systemic IGF-1 can feedback on hepatic IGF-1 mRNA
expression in the GH-deﬁcient state. Our IGF-1R
aP2Cre
mice have normal GH serum concentrations (Table 1),
suggesting that under normal GH levels, hepatic IGF-1
expression does not depend on the same feedback mech-
anism. Moreover, we cannot explain why increased IGF-1
levels did not cause decreased GH serum concentrations.
Therefore, we cannot exclude that reduction of IGF-1R
receptor signaling in individual tissues causes a disruption
of physiological feedback mechanisms in other systems or
tissues. Adipose tissue–derived signals other than circu-
lating IGF-1, GH, and/or IGF-2 might cause increased
circulating IGF-1 levels and increased IGF-1 expression in
liver and adipose tissue. Further studies are necessary to
characterize these signals.
Circulating IGF-1 was shown to reduce IGF-1 mRNA
expression in liver, whereas GH increases IGF-1 gene
expression (23). In our model with normal GH but in-
creased IGF-1 serum concentrations, one would expect
decreased rather than the observed increased hepatic
IGF-1 mRNA expression. One hypothesis is that lack of
IGF-1R signaling in adipose tissue generates signals that
indirectly increase both adipose and hepatic IGF-1 expres-
sion. However, GH and IGF-2 receptor expressions were
indistinguishable between IGF-1R
aP2Cre and control
mice in both liver and adipose tissue, suggesting that no
liver-speciﬁc compensatory mechanism accounts for the
unsuppressed IGF-1 mRNA expression in liver. In par-
allel to increased IGF-1 serum concentrations, circulat-
ing IGFBP-3, but not IGFBP-1 and -2, was signiﬁcantly
increased in IGF-1R
aP2Cre mice. Overexpression of hu-
man IGFBP-3 in transgenic mice results in selective
organomegaly, including liver and heart (24), suggesting
that increased IGFBP-3 levels contribute to organo-
megaly in IGF-1R
aP2Cre mice.
Increased circulating IGF-1 by 50% was shown to im-
prove glucose tolerance in mice with a liver-speciﬁc
overexpression of the Igf-1 gene (22). Interestingly, we did
not observe any improvement of glucose tolerance and
insulin sensitivity in IGF-1R
aP2Cre mice, suggesting that
20% increased IGF-1 levels are not sufﬁcient to enhance
whole-body insulin sensitivity. IGF-1R
aP2Cre mice do not
exhibit signiﬁcant metabolic alterations. Interestingly, at
the age of 12 weeks, when growth curves diverge, fasting
blood glucose concentrations are signiﬁcantly higher in
IGF-1R
aP2Cre than in controls. Because glucose tolerance is
normal at this age, it is difﬁcult to establish causality for
elevated glucose concentrations. Higher adipose tissue
mass could contribute to these metabolic alterations. We
also found lower adiponectin serum concentrations in
IGF-1R
aP2Cre mice of both sexes. Lower circulating adi-
ponectin levels further suggest that metabolic alterations
in IGF-1R
aP2Cre mice at 12 weeks of age are a consequence
of increased fat mass. Serum adiponectin negatively cor-
relates with fat mass in mice (16) and men (28). Insulin
and IGF-1 are capable of binding to each other’s receptor,
although with different afﬁnities (29). Mice with a targeted
disruption of the insulin receptor in adipose tissue (FIRKO
mice) are protected from obesity and its metabolic alter-
ations (16). Moreover, these mice exhibit speciﬁc morpho-
logical changes in adipose tissue, which could be due to a
defect in adipose tissue development. We therefore ex-
pected alterations in adipose tissue of IGF-1R
aP2Cre,b e -
cause IGF-1R was shown to be important in the growth
and differentiation of adipocytes in vitro (9). Despite
similarities in the structure and intracellular signaling
between insulin and IGF-1Rs, we did not ﬁnd a severe
metabolic phenotype in mice lacking the IGF-1R in adi-
pose tissue. However, we found signiﬁcantly increased
insulin-stimulated glucose uptake into isolated adipocytes
from IGF-1R
aP2Cre mice, suggesting increased glucose up-
take and subsequent increase in lipogenesis as primary
causes leading to increased lipid load per adipocyte and
adipose tissue hypertrophy in IGF-1R
aP2Cre mice.
This further suggests that insulin receptor signaling is
more important for fuel metabolism, whereas IGF-1R
mediates growth, and that one receptor cannot function-
ally compensate for the other receptor’s absence (13).
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cytes is not crucial for the growth, development, or
differentiation of adipose tissue in vivo. Unexpectedly,
both the number and the size of adipocytes is increased in
adipose tissue of IGF-1R
aP2Cre mice, either suggesting that
intact IGF-1R is not necessary for adipose tissue develop-
ment or that other mechanisms exist in vivo, which can
compensate for the disruption of IGF-1R. In accordance
with our results, it was recently shown that most IGF
receptor–deﬁcient adipocyte cell lines were capable of
normal differentiation (13). Moreover, important markers
of adipogenesis, including peroxisome proliferator–acti-
vated receptor-
 and GLUT4, were expressed despite the
lack of IGF-1R (13). One potential mechanism could be
that insulin receptor mediates the IGF-1 effects on growth
and differentiation in vivo. This hypothesis is supported by
increased insulin receptor gene expression in adipose
tissue of IGF-1R
aP2Cre mice. However, in vitro there was no
compensation of insulin receptor when the IGF-1R was
absent. Therefore, it appears that IGF-1R is not crucial for
adipose tissue development. Interestingly, adipocytes
from IGF-1R
aP2Cre mice were more sensitive to insulin-
stimulated glucose uptake than adipocytes from control
mice. Our ﬁndings are in accordance with previously
reported increased insulin sensitivity in IGF-1R–deﬁcient
brown adipocytes (30). Moreover, downregulation of
IGF-1R in breast cancer cells was shown to increase
insulin sensitivity (31). Diminished IGF-1R/insulin recep-
tor hybrid receptor formation resulting in enhanced holo–
insulin receptor formation could contribute to increased
insulin sensitivity in IGF-1R–deﬁcient adipocytes. In addi-
tion, increased insulin receptor number might enhance
insulin effects on IGF-1R
aP2Cre adipocytes.
In conclusion, IGF-1R signaling in adipocytes is not
crucial for the development and differentiation of adipose
tissue in vivo but seems to participate in the regulation of
IGF-1 serum concentration.
ACKNOWLEDGMENTS
M.B. has received Deutsche Forschungsgemeinschaft
Grant BL 580/3-1, Clinical Research group Atherobesity
KFO 152 Project BL 833/1-1, and Project B24 from the
Interdisciplinary Center of Clinical Research Leipzig at the
Faculty of Medicine of the University of Leipzig.
REFERENCES
1. Dupont J, Holzenberger M: Biology of insulin-like growth factors in
development. Birth Defects Res 69:257–271, 2003
2. Accili D, Drago J, Lee EJ, Johnson MD, Cool MH, Salvatore P, Asico LD,
Jose LA, Taylor SI, Westphal H: Early neonatal death in mice homozygous
for a null allele of the insulin receptor gene. Nat Genet 12:106–109, 1996
3. Liu JP, Baker J, Perkins A, Robertson EJ, Efstratiadis A: Mice carrying null
mutations of the genes encoding insulin-like growth factor I (IGF-1) and
type 1 IGF receptor (Igf1r). Cell 75:59–72, 1993
4. Holzenberger M, Dupont J, Ducos B, Leneuve P, Geloen A, Even PC,
Cervera P, Le Bouc Y: IGF-1 receptor regulates lifespan and resistance to
oxidative stress in mice. Nature 421:182–187, 2003
5. Zhang M, Xuan S, Bouxsein ML, von Stechow D, Akeno N, Faugere MC,
Malluche H, Zhao G, Rosen CJ, Efstratiadis A, Clemens TL: Osteoblast-
speciﬁc knockout of the insulin-like growth factor (IGF) receptor gene
reveals an essential role of IGF signaling in bone matrix mineralization.
J Biol Chem 277:44005–44012, 2002
6. Fernandez AM, Dupont J, Farrar RP, Lee S, Stannard B, Le Roith D:
Muscle-speciﬁc inactivation of the IGF-I receptor induces compensatory
hyperplasia in skeletal muscle. J Clin Invest 109:347–355, 2002
7. Coleman ME, DeMayo F, Yin KC, Lee HM, Geske R, Montgomery C,
Schwartz RJ: Myogenic vector expression of insulin-like growth factor I
stimulates muscle cell differentiation and myoﬁber hypertrophy in trans-
genic mice. J Biol Chem 270:12109–12116, 1995
8. Kulkarni RN, Holzenberger M, Shih DQ, Ozcan U, Stoffel M, Magnuson MA,
Kahn CR: Beta-cell-speciﬁc deletion of the Igf1 receptor leads to hyperin-
sulinemia and glucose intolerance but does not alter beta-cell mass. Nat
Genet 31:111–115, 2002
9. Smith PJ, Wise LS, Berkowitz R, Wan C, Rubin CS: Insulin-like growth
factor-I is an essential regulator of the differentiation of 3T3–L1 adipo-
cytes. J Biol Chem 263:9402–9408, 1988
10. Scavo LM, Karas M, Murray M, Le Roith D: Insulin-like growth factor-I
stimulates both cell growth and lipogenesis during differentiation of
human mesenchymal stem cells into adipocytes. J Clin Endocrinol Metab
89:3543–3553, 2004
11. Abel ED, Peroni OD, Kim JK, Kim YB, Boss O, Hadro E, Minnemann T,
Shulman GI, Kahn BB: Adipose-selective targeting of the GLUT4 gene
impaires insulin action in muscle and liver. Nature 409:729–733, 2001
12. Etherton TD, Thompson EH, Allen CE: Improved techniques for studies of
adipocyte cellularity and metabolism. J Lipid Res 18:552–557, 1977
13. Entingh-Pearsall A, Kahn CR: Differential roles of the insulin and insulin-
like growth factor-I (IGF-I) receptors in response to insulin and IGF-I.
J Biol Chem 279:38016–38024, 2004
14. Ross SR, Graves RA, Greenstein A, Platt KA, Shyu HL, Mellovitz B,
Spiegelman BM: A fat-speciﬁc enhancer is the primary determinant of gene
expression for adipocyte P2 in vivo. Proc Natl Acad SciUSA87:9590–
9594, 1990
15. Blu ¨her M, Kahn BB, Kahn CR: Extended longevity in mice lacking the
insulin receptor in adipose tissue. Science 299:572–574, 2003
16. Blu ¨her M, Michael MD, Peroni OD, Ueki K, Carter N, Kahn BB, Kahn CR:
Adipose tissue selective insulin receptor knockout protects against obesity
and obesity-related glucose intolerance. Dev Cell 3:25–38, 2002
17. Urs S, Harrington A, Liaw L, Small D: Selective expression of an aP2/fatty
acid binding protein 4-Cre transgene in non-adipogenic tissues during
embryonic development. Transgenic Res 15:647–653, 2006
18. Holzenberger M, Leneuve P, Hamard G, Ducos B, Perin L, Binoux M, Le
Bouc Y: A targeted partial invalidation of the Igf1r gene in mice causes a
postnatal growth deﬁcit. Endocrinology 141:2557–2566, 2000
19. Ezzat S: Hepatobiliary and gastrointestinal manifestations of acromegaly.
Dig Dis 10:173–180, 1992
20. Colao A, Vitale G, Pivonello R, Ciccarelli A, Di Somma C, Lombardi G: The
heart: an end-organ of GH action. Eur J Endocrinol 151:S93–S101, 2004
21. Mathews LS, Hammer RE, Behringer RR, D’Ercole AJ, Bell GI, Brinster RL,
Palmiter RD: Growth enhancement of transgenic mice expressing human
insulin-like growth factor I. Endocrinology 123:2827–2833, 1988
22. Liao L, Dearth RK, Zhou S, Britton OL, Lee AV, Xu J: Liver-speciﬁc
overexpression of the insulin-like growth factor-I enhances somatic
growth and partially prevents the effects of growth hormone deﬁciency.
Endocrinology 147:3877–3888, 2006
23. Lemmey AB, Glassford J, Flick-Smith HC, Holly JM, Pell JM: Differential
regulation of tissue insulin-like growth factor-binding protein (IGFBP)-3,
IGF-I and IGF type 1 receptor mRNA levels, and serum IGF-I and IGFBP
concentrations by growth hormone and IGF-I. J Endocrinol 154:319–328,
1997
24. Butler AA, Ambler GR, Breier BH, LeRoith D, Roberts CT Jr, Gluckman PD:
Growth hormone (GH) and insulin-like growth factor-I (IGF-I) treatment of
the GH-deﬁcient dwarf rat: differential effects on IGF-I transcription start
site expression in hepatic and extrahepatic tissues and lack of effect on type
I IGF receptor mRNA expression. Mol Cell Endocrinol 101:321–330, 1994
25. Butler AA, LeRoith D: Minireview: tissue-speciﬁc versus generalized gene
targeting of the igf1 and igf1r genes and their roles in insulin-like growth
factor physiology. Endocrinology 142:1685–1688, 2001
26. Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, LeRoith D: Normal
growth and development in the absence of hepatic insulin-like growth
factor I. Proc Natl Acad SciUSA96:7324–7329, 1999
27. Murphy LJ, Molnar P, Lu X, Huang H: Expression of human insulin-like
growth factor-binding protein-3 in transgenic mice. J Mol Endocrinol
15:293–303, 1995
28. Tschritter O, Fritsche A, Thamer C, Haap M, Shirkavand F, Rahe S, Staiger
H, Maerker E, Haring H, Stumvoll M: Plasma adiponectin concentrations
predict insulin sensitivity of both glucose and lipid metabolism. Diabetes
52:239–243, 2003
29. Steele-Perkins G, Turner J, Edman JC, Hari J, Pierce SB, Stover C, Rutter
WJ, Roth RA: Expression and characterization of a functional human
insulin-like growth factor I receptor. J Biol Chem 263:11486–11492, 1988
30. Mur C, Valverde AM, Kahn CR, Benito M: Increased insulin sensitivity in
IGF-I receptor–deﬁcient brown adipocytes. Diabetes 51:743–754, 2002
31. Zhang H, Pelzer AM, Kiang DT, Yee D: Down-regulation of type I insulin-
like growth factor receptor increases sensitivity of breast cancer cells to
insulin. Cancer Res 67:391–397, 2007
ROLE OF IGF-1 IN ADIPOCYTES
2082 DIABETES, VOL. 57, AUGUST 2008